MX352941B - Metodo para la preparacion de una composicion que contiene portador de oxigeno estable al calor que facilita la reticulacion beta-beta. - Google Patents

Metodo para la preparacion de una composicion que contiene portador de oxigeno estable al calor que facilita la reticulacion beta-beta.

Info

Publication number
MX352941B
MX352941B MX2014002327A MX2014002327A MX352941B MX 352941 B MX352941 B MX 352941B MX 2014002327 A MX2014002327 A MX 2014002327A MX 2014002327 A MX2014002327 A MX 2014002327A MX 352941 B MX352941 B MX 352941B
Authority
MX
Mexico
Prior art keywords
beta
hemoglobin
cross
linking
heat stable
Prior art date
Application number
MX2014002327A
Other languages
English (en)
Other versions
MX2014002327A (es
Inventor
Lou Wong Bing
Yi Kwok Sui
Chu Butt Kwok
Original Assignee
Billion King International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Billion King International Ltd filed Critical Billion King International Ltd
Publication of MX2014002327A publication Critical patent/MX2014002327A/es
Publication of MX352941B publication Critical patent/MX352941B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a métodos para la preparación de una composición farmacéutica que contiene portador de oxígeno a base de hemoglobina estable al calor tal que se favorece la reticulación beta-beta. Usando los métodos de la presente invención, se puede controlar la afinidad a oxígeno de la molécula resultante de modo que se producen portadores de oxígeno a base de hemoglobina adaptados para aplicaciones específicas. La hemoglobina reticulada de menor afinidad a oxígeno es útil para aplicaciones que requieren rápida oxigenación de tejido (por ejemplo, choque hemorrágico) en tanto que la hemoglobina reticulada de mayor afinidad a oxígeno es útil para aplicaciones que requieren una menor velocidad de oxigenación (por ejemplo, terapia adjunta de cáncer). Se requiere una hemoglobina tetramérica no polimérica reticulada estable al calor y altamente purificada que tiene reticulación beta-beta de más de 40-60% y adecuada para el uso en mamíferos sin producir lesión renal ni vasoconstricción. Un paso de procesamiento térmico de alta temperatura y corto tiempo (HTST) se realiza para remover efectivamente cualquier hemoglonia dimérica indeseada, hemoglobina tetramérica no reticulada e impurezas de proteína plasmática.
MX2014002327A 2011-08-31 2012-08-23 Metodo para la preparacion de una composicion que contiene portador de oxigeno estable al calor que facilita la reticulacion beta-beta. MX352941B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161529279P 2011-08-31 2011-08-31
US13/225,797 US20130052232A1 (en) 2011-08-31 2011-09-06 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US13/275,366 US8106011B1 (en) 2011-08-31 2011-10-18 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
PCT/US2012/051959 WO2013032828A2 (en) 2011-08-31 2012-08-23 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking

Publications (2)

Publication Number Publication Date
MX2014002327A MX2014002327A (es) 2014-09-15
MX352941B true MX352941B (es) 2017-12-14

Family

ID=45508128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002327A MX352941B (es) 2011-08-31 2012-08-23 Metodo para la preparacion de una composicion que contiene portador de oxigeno estable al calor que facilita la reticulacion beta-beta.

Country Status (21)

Country Link
US (2) US20130052232A1 (es)
EP (1) EP2750700B1 (es)
JP (1) JP6148673B2 (es)
KR (1) KR101794932B1 (es)
CN (1) CN103796671A (es)
AP (1) AP3848A (es)
AU (1) AU2012300475B2 (es)
BR (1) BR112014003480A2 (es)
CA (1) CA2844510C (es)
CL (1) CL2014000328A1 (es)
DK (1) DK2750700T3 (es)
EA (1) EA027238B1 (es)
ES (1) ES2664589T3 (es)
IL (1) IL231198A0 (es)
MA (1) MA35358B1 (es)
MX (1) MX352941B (es)
MY (1) MY163300A (es)
SG (1) SG2014011498A (es)
TW (2) TWI408145B (es)
WO (1) WO2013032828A2 (es)
ZA (1) ZA201401518B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781489B (zh) 2011-09-06 2017-03-29 黄炳镠 用于基于血红蛋白的氧载体的口服递送
US10029001B2 (en) * 2012-03-29 2018-07-24 William Schindler Diaspirin crosslinked pegylated hemoglobin
NZ709825A (en) 2013-01-07 2019-08-30 Omniox Inc Polymeric forms of h-nox proteins
JP6392855B2 (ja) * 2013-05-13 2018-09-19 ビジョン グローバル ホールディングス リミテッドＶｉｓｉｏｎ Ｇｌｏｂａｌ Ｈｏｌｄｉｎｇｓ Ｌｔｄ． がん治療および診断イメージングのための修飾ヘモグロビンベース系治療剤を含む医薬組成物
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US9763889B2 (en) 2015-06-29 2017-09-19 Billion King International Ltd. Oral delivery system for hemoglobin based oxygen carriers
US10052290B2 (en) 2016-02-04 2018-08-21 Billion King International Ltd. Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLUTER SUBSTITUTES CONTAINING HEMOGLOBIN AND PROCESS FOR THEIR PRODUCTION
JP2022546993A (ja) * 2019-08-29 2022-11-10 ビリオン キング インターナショナル リミテッド チオスクシニル架橋ヘモグロビン類似体、ならびにその使用方法及び調製方法
CN110522904A (zh) * 2019-09-09 2019-12-03 润方（北京）生物医药研究院有限公司 一种抑制血压升高的聚合血红蛋白
WO2021072194A1 (en) * 2019-10-11 2021-04-15 Medical Technology Associates Ii, Inc. Stabilized hemoglobin compositions and pharmaceutical formulations thereof
WO2022184005A1 (en) * 2021-03-01 2022-09-09 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
FR2548671B1 (fr) 1983-07-07 1986-05-02 Merieux Inst Procede de preparation de globine a partir d'hemoglobine et globine obtenue par ce procede
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
USRE34271E (en) 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US5464814A (en) 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
JPH0750329B2 (ja) 1986-06-23 1995-05-31 富士写真フイルム株式会社 画像形成材料
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5753616A (en) 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5189146A (en) 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
JP2592973B2 (ja) 1988-06-15 1997-03-19 バクスター インターナショナル インコーポレーテッド 架橋ヘモグロビンの精製方法
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5725839A (en) 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5817632A (en) 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
DE69534187T2 (de) 1994-05-13 2005-11-17 Miltenyi Biotec Gmbh Sterile und pyrogenfreie säulen, gekoppelt mit einem protein, zum binden und entfernen von substanzen aus dem blut
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5741894A (en) 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
WO1997019956A1 (en) 1995-11-30 1997-06-05 Somatogen, Inc. Method for control of functionality during cross-linking of hemoglobins
BR9612569A (pt) 1996-03-21 1999-12-28 Sengewald Verpackungen Gmbh Folha de várias camadas, processo para a sua preparação e sua aplicação
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
US6054427A (en) 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
US5814601A (en) 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
JP4643004B2 (ja) 1998-01-06 2011-03-02 シーラス コーポレイション 生体材料中の病原体不活性化剤をクエンチするための方法
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US6518010B2 (en) 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
US20030065149A1 (en) 2001-04-18 2003-04-03 Northfield Laboratories Stabilized hemoglobin solutions
JP4260417B2 (ja) 2001-05-23 2009-04-30 ノバルティス アクチエンゲゼルシャフト 溶液を輸送し脱酸素するためのシステム及び方法
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
WO2004058291A1 (en) 2002-12-23 2004-07-15 Albert Einstein College Of Medicine Of Yeshiva University Modified hemoglobin and methods of making same
WO2004066953A2 (en) 2003-01-29 2004-08-12 Northfield Laboratories, Inc. Polymerized hemoglobin solutions having reduced amount of tetramer and method for preparing
EP1838355B1 (en) 2004-10-29 2013-08-14 Cerus Corporation Improved quenching methods for red blood cell inactivation process
WO2007065265A1 (en) 2005-12-08 2007-06-14 Ronald Kluger Cross-linking reagents for hemoglobin and hemoglobin products cross-linked therewith
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US7795401B2 (en) 2006-09-06 2010-09-14 National Chung Cheng University Modified hemoglobin with allosteric effector conjugated
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
TWI526218B (zh) 2016-03-21
AP2014007545A0 (en) 2014-03-31
SG2014011498A (en) 2014-04-28
WO2013032828A8 (en) 2013-07-04
TW201313736A (zh) 2013-04-01
AU2012300475B2 (en) 2017-04-06
TWI408145B (zh) 2013-09-11
CL2014000328A1 (es) 2014-07-11
DK2750700T3 (en) 2018-04-16
EP2750700A2 (en) 2014-07-09
MA35358B1 (fr) 2014-08-01
AP3848A (en) 2016-09-30
JP6148673B2 (ja) 2017-06-14
TW201341396A (zh) 2013-10-16
MY163300A (en) 2017-09-15
ZA201401518B (en) 2014-12-23
KR101794932B1 (ko) 2017-11-07
IL231198A0 (en) 2014-04-30
WO2013032828A3 (en) 2013-05-10
EP2750700B1 (en) 2017-12-27
US20130052232A1 (en) 2013-02-28
MX2014002327A (es) 2014-09-15
EA201400169A1 (ru) 2014-06-30
BR112014003480A2 (pt) 2017-03-14
EA027238B1 (ru) 2017-07-31
JP2014525441A (ja) 2014-09-29
ES2664589T3 (es) 2018-04-20
KR20140060510A (ko) 2014-05-20
NZ620913A (en) 2016-03-31
US8106011B1 (en) 2012-01-31
CA2844510C (en) 2018-09-11
CN103796671A (zh) 2014-05-14
EP2750700A4 (en) 2015-03-11
AU2012300475A1 (en) 2014-02-27
CA2844510A1 (en) 2013-03-07
WO2013032828A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
MX352941B (es) Metodo para la preparacion de una composicion que contiene portador de oxigeno estable al calor que facilita la reticulacion beta-beta.
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
BR112012000617B8 (pt) método para a preparação de uma composição farmacêutica contendo veículo de oxigênio estável de calor
HK1166719A1 (en) A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
MY186337A (en) Cd123 binding agents and uses thereof
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
MX2016007311A (es) Metodos para tratar canceres.
MX2010008863A (es) Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c.
EA201171199A1 (ru) Способ очистки рекомбинантного фсг
MY169908A (en) A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
EA201691235A1 (ru) Модифицированные серпины для лечения нарушений свертываемости крови
EA201592125A1 (ru) Системы для адсорбции при переменной температуре и способы очистки текучих сред, использующие такие системы
RU2015119523A (ru) Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
WO2012122028A3 (en) Pyrazinoisoquinoline compounds
EA201590820A1 (ru) Производные 4-карбоксамидоизоиндолинона в качестве селективных ингибиторов parp-1
MX345534B (es) Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas.
MX347245B (es) Composiciones para el tratamiento de úlceras periféricas de diversos orígenes.
RU2015134356A (ru) Пептид
WO2006110577A3 (en) Use of fril proteins for reducing the production of pro-inflammatory cytokines
PH12016501132A1 (en) A process for preparing a composition of pegylated proteins
TH143365A (th) วิธีการสำหรับการเตรียมองค์ประกอบที่มีสารพาหะของออกซิเจนที่เสถียรต่อความร้อนที่ง่ายต่อการครอสลิงค์ของเบต้า-เบต้า
TH77663B (th) วิธีการสำหรับการเตรียมองค์ประกอบทางเภสัชกรรมที่มีสารพาหะของออกซิเจนที่เสถียรต่อความร้อน
RU2015104076A (ru) Композиция с факторами роста для применения в интраназальном лечении нейродегенеративного заболевания или других заболеваний центральной нервной системы и способ ее получения
TH122386B (th) วิธีการสำหรับการเตรียมองค์ประกอบทางเภสัชกรรมที่มีสารพาหะของออกซิเจนที่เสถียรต่อความร้อน

Legal Events

Date Code Title Description
FG Grant or registration